EP2090297A1 — Formulations of flibanserin
Assigned to Boehringer Ingelheim International GmbH · Expires 2009-08-19 · 17y expired
What this patent protects
The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of Flibanserin, at least one pharmaceutically acceptable pH modifier and at least one pharmaceutically acceptable excipient achieving and maintaining supersaturation.
USPTO Abstract
The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of Flibanserin, at least one pharmaceutically acceptable pH modifier and at least one pharmaceutically acceptable excipient achieving and maintaining supersaturation.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.